Monitoring ctDNA for recurrence in gastric cancer patients after surgery
Official title: Personalized ctDNA-MRD in Recurrence Monitoring for Gastric Cancer Patients Undergoing Perioperative Treatment Combined With Curative Surgical Resection
Run by Peking University · NCT06893133 · Data updated 2026-11-12
This study is testing if checking for cancer DNA in the blood can help doctors find out if gastric cancer patients are at risk of their cancer coming back after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 110 (estimated) |
| Sponsor | Peking University Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | April 8, 2025 |
| Main results expected | December 30, 2026 |
| Study ends | April 30, 2027 |
| Registry record updated | April 21, 2026 |
| Trial ID | NCT06893133 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with pathologically confirmed stage II-III gastric or gastroesophageal junction adenocarcinoma who have received neoadjuvant therapy and curative surgery.
✕Probably not a fit
Patients who have not undergone R0 resection surgery or those with other serious diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to monitor gastric cancer patients who have undergone neoadjuvant therapy followed by curative resection by utilizing circulating tumor DNA (ctDNA) to detect molecular residual disease (MRD). The study will analyze the relationship between ctDNA-MRD status and tumor recurrence, assessing its sensitivity and specificity in predicting recurrence compared to traditional imaging techniques. By identifying residual tumor signals in the blood, the study seeks to provide early warnings of recurrence, potentially allowing for timely interventions.
Why it matters
Potential benefit: If successful, this approach could enable earlier detection of gastric cancer recurrence, leading to improved patient outcomes through timely interventions.
How similar studies have gone: Previous studies have shown that ctDNA-MRD testing can identify recurrences earlier than traditional imaging methods, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients have received neoadjuvant therapy and radical resection (R0). 2. Pathologically confirmed ypTNM stage II-III gastric or gastroesophageal junction adenocarcinoma. 3. Patients must be able to provide sufficient fresh tissue/biopsies or minimum 5-10 FFPE sections for NGS-WES analysis. 4. Patients must be able to follow the study visit schedule and be willing to cooperate with the study by providing blood samples at the indicated time point. Exclusion Criteria: 1. Patients who could not receive enhanced CT, gastroscopy and other routine review after surgery. 2. Patients who could not perform WES or ctDNA-MRD detection for various reasons after surgery. 3. Other cases considered unsuitable for inclusion by researchers.
Where it's running
-
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Ziyu Li, MD.,PhD
- Email: ziyu_li@hsc.pku.edu.cn
- Phone: 0086-10-88121122
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.